Xu Liu is the lead sponsor of 5 current clinical trials in our China register. None of its ClinicalTrials.gov trials is recruiting at the moment. All registered phases are Not applicable. The drugs named most often in its trials are Mavacamten. The most-studied condition is Persistent Atrial Fibrillation.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
EGM Guided PFA for PerAF
NCT06729866 · ClinicalTrials.gov ↗ · Persistent Atrial Fibrillation
|
Not applicable | Active, closed | 2024-09 | China |
|
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
NCT06947590 · ClinicalTrials.gov ↗ · HCM - Hypertrophic Cardiomyopathy, Mavacamten
Drug: Mavacamten |
Not applicable | Active, closed | 2025-04 | China |
|
Pulsed-Field Ablation With/Without Electrogram Mapping
NCT07541989 · ClinicalTrials.gov ↗ · Non-paroxysmal Atrial Fibrillation
|
Not applicable | Active, closed | 2024-09 | China |
|
Impact of Periodontal Therapy on AF Recurrence Post-Ablation in High-Inflammatory Burden Patients
NCT06892808 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Periodontitis
|
Not applicable | Active, closed | 2025-03 | China |
|
Optimal Ablation Strategies for Persistent AF With HF
NCT07153718 · ClinicalTrials.gov ↗ · Heart Failure, Persistent Atrial Fibrillation
|
Not applicable | Active, closed | 2021-01 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 0 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Boston Scientific Corporation | 4 |
| Medtronic Cardiac Ablation Solutions | 3 |
| The Third People's Hospital of Chengdu | 2 |
Sponsors with the most current trials registered for this condition.
Xu Liu is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 5 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Mavacamten (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.